このエントリーをはてなブックマークに追加
ID 52840
FullText URL
Author
Itoh, Mitsuya
Iwamoto, Takayuki
Matsuoka, Junji Kaken ID
Nogami, Tomohiro
Motoki, Takayuki
Shien, Tadahiko ORCID Kaken ID publons
Taira, Naruto Kaken ID
Niikura, Naoki
Hayashi, Naoki
Ohtani, Shoichiro
Higaki, Kenji
Fujiwara, Toshiyoshi ORCID Kaken ID researchmap
Doihara, Hiroyoshi Kaken ID researchmap
Symmans, W. Fraser
Pusztai, Lajos
Abstract
We examined estrogen receptor (ER) mRNA expression and molecular subtypes in stage I-III breast cancers that are progesterone receptor (PR) positive but ER and HER2 negative by immunohistochemistry (IHC) or fluorescent in situ hybridization. The ER, PR, and HER2 status was determined by IHC as part of routine clinical assessment (N = 501). Gene expression profiling was done with the Affymetrix U133A gene chip. We compared expressions of ESR1 and MKI67 mRNA, distribution of molecular subtypes by the PAM50 classifier, the sensitivity to endocrine therapy index, and the DLDA30 chemotherapy response predictor signature among ER/PR-positive (n = 223), ER-positive/PR-negative (n = 73), ER-negative/PR-positive (n = 20), and triple-negative (n = 185) cancers. All patients received neoadjuvant chemotherapy with an anthracycline and taxane and had adjuvant endocrine therapy only if ER or PR > 10 % positive. ESR1 expression was high in 25 % of ER-negative/PR-positive, in 79 % of ER-positive/PR-negative, in 96 % of ER/PR-positive, and in 12 % of triple-negative cancers by IHC. The average MKI67 expression was significantly higher in the ER-negative/PR-positive and triple-negative cohorts. Among the ER-negative/PR-positive patients, 15 % were luminal A, 5 % were Luminal B, and 65 % were basal like. The relapse-free survival rate of ER-negative/PR-positive patients was equivalent to ER-positive cancers and better than the triple-negative cohort. Only 20-25 % of the ER-negative/PR-positive tumors show molecular features of ER-positive cancers. In this rare subset of patients (i) a second RNA-based assessment may help identifying the minority of ESR1 mRNA-positive, luminal-type cancers and (ii) the safest clinical approach may be to consider both adjuvant endocrine and chemotherapy.
Keywords
Estrogen receptor
Progesteron receptor
cDNA microarray
Breast cancer
Hormone therapy
Note
The final publication is available at www.springerlink.com
Published Date
2014-01
Publication Title
Breast Cancer Research and Treatment
Volume
volume143
Issue
issue2
Publisher
Springer
Start Page
403
End Page
409
ISSN
0167-6806
NCID
AA10623184
Content Type
Journal Article
Related Url
http://ousar.lib.okayama-u.ac.jp/metadata/52821
language
英語
Copyright Holders
© Springer Science+Business Media New York 2013
File Version
author
Refereed
True
DOI
Web of Science KeyUT